Sorafenib is a multi-kinase inhibitor of Raf-1 and B-Raf, which can simultaneously inhibit a variety of intracellular kinases involved in tumor cell signal transduction, angiogenesis and apoptosis, and exert anti-tumor effects. This evidence concerns the gene BRAF and neoplasm.